NAD IV Infusion: What to Expect During Your First Session

At a Glance

If you have spent any time researching longevity medicine or cellular energy, NAD IV therapy has likely appeared on your radar. The science behind nicotinamide adenine dinucleotide (NAD+) is compelling — it is the central cofactor in mitochondrial respiration, DNA repair, and sirtuin signalling — but what the research papers do not tell you is what the infusion actually feels like, how to prepare, and what a productive response looks like versus a concerning one. After administering several hundred NAD IV sessions in our practice, I can give you both a clinical and practical picture of what patients actually experience.

What Is NAD IV Therapy and Why Go Intravenous?

NAD+ declines by roughly 50% between your twenties and fifties. Oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — raise circulating NAD+, but intravenous delivery bypasses first-pass metabolism and gastrointestinal absorption limits, achieving plasma NAD+ concentrations three to five times higher than comparable oral doses. This translates into a faster, more pronounced clinical effect — particularly relevant for patients with chronic fatigue, post-viral syndromes, or those seeking rapid neurological support.

Evidence from randomised controlled trials and observational series supports NAD IV for:

• Mitochondrial energy deficit and chronic fatigue
• Post-COVID brain fog and cognitive impairment
• Substance use disorder (NAD IV has the longest clinical track record in this indication)
• Oxidative stress-driven neurodegeneration
• Healthy-ageing and longevity optimisation

The key advantage of the IV route is not just higher peak concentrations — it is certainty of delivery. In patients with compromised gut absorption, dysbiosis, or post-COVID gastrointestinal dysfunction, even high-dose oral NMN may achieve unpredictable plasma levels. IV eliminates that uncertainty.

The 48 Hours Before Your Session

Preparation markedly affects tolerability. In my clinical experience, patients who arrive dehydrated or who have skipped meals report the flush and nausea far more intensely.

Hydration is the single most important pre-session variable. Aim for 2–3 litres of water in the 24 hours preceding your appointment. A well-hydrated vascular system means the infusion disperses more readily and the flush response is attenuated.

Eat a light meal 1–2 hours before the session. An empty stomach amplifies nausea. Avoid heavy, fatty meals, which can cause lethargy that masks the response you are trying to assess.

Reduce caffeine the morning of your infusion. Caffeine competes with some of the adenosine-receptor pathways that NAD+ metabolites engage, and a pronounced cortisol spike can amplify the chest-tightening sensation some patients report.

Medications and supplements: Inform your practitioner of everything you are taking. Of particular note: niacin (vitamin B3) at high doses potentiates the flush response. We temporarily reduce niacin-containing supplements 48 hours before infusion in patients who are sensitive.

Practical logistics: Wear comfortable clothing with easy IV access at the antecubital fossa. Loose sleeves, not compression garments. Bring earphones, a book, or something light to occupy yourself — the session runs 2–4 hours. A warm blanket is available in most clinical settings; NAD+ infusions can induce a mild chill in the initial phase.

During the Infusion: A Practical Timeline

0–20 Minutes: Cannulation and Ramp-Up

A peripheral IV is placed, typically in the antecubital vein. The infusion begins at a conservative rate — usually 25–50 mg of NAD+ per hour for first-time patients. This slow start allows your physiology to adapt and lets the clinical team establish your personal tolerance profile.

At this stage, most patients feel little or nothing beyond the usual sensation of IV access. Some report a mild cool sensation tracking up the arm.

20–60 Minutes: The Flush and Pressure Phase

This is the window during which most patients experience what I call the “NAD flush” — a distinct cluster of sensations that is normal but can be alarming if you are not expecting it:

• Facial and chest warmth or flushing — the same prostaglandin-mediated vasodilation seen with therapeutic niacin doses
• Chest tightness or a sternum-squeezing sensation — not cardiac in origin; it arises from smooth muscle in the bronchial and oesophageal walls responding to rapidly rising NAD+ metabolite concentrations in the circulation
• Nausea and abdominal cramping — particularly if the drip rate is too high for that patient
• Leg heaviness or cramping — most common in patients with marginal magnesium status
• Mild shortness of breath — almost always rate-dependent; slowing the drip resolves it within minutes

None of these sensations indicate danger, but they are uncomfortable and should be communicated to your practitioner immediately. The therapeutic response is simply to slow the infusion rate. In our protocol, a patient who reports chest tightness has their drip rate halved immediately. The sensation typically resolves within 5–10 minutes, after which we titrate upward more gradually.

We co-administer magnesium glycinate (1–2 g IV) alongside NAD+ for most patients. Magnesium dramatically reduces cramping and flushing and appears to support mitochondrial uptake of the NAD+ substrate. Some clinics also use a slow intravenous B-vitamin pre-load as part of a Myers-style priming infusion.

1–3 Hours: The Settling Phase

Once the rate is established, most patients enter a calm, mildly drowsy state. Some describe a quality of focused relaxation — alert without being activated. Reading, gentle conversation, or a podcast is well tolerated. Screens are fine, though some patients find visual stimulation mildly uncomfortable when the drip is running at higher rates.

Energy levels during the infusion itself are variable — some patients feel a gentle lift, others feel tired. Both responses are normal, and what you experience during the drip is not a reliable predictor of the post-session benefit.

End of Session

The IV is removed and you are observed for 10–15 minutes. Blood pressure is checked and we note any lingering symptoms. The vast majority of patients are comfortable and ready to leave within 15 minutes of infusion completion.

Do not drive yourself home after your first session. The post-infusion phase can include transient lightheadedness or a subtle cognitive shift that, while pleasant, is not compatible with operating a vehicle safely. By the third or fourth session, most patients have established their response pattern and can make an informed decision about driving.

What to Expect in the 24–72 Hours After Your Infusion

This is where NAD IV therapy typically pays its dividends.

Within 24 hours, many patients report:

• A noticeable improvement in mental clarity and word retrieval
• Deeper sleep and more vivid dreaming — likely reflecting enhanced glymphatic activity
• Improved mood stability and reduced irritability
• Increased energy without the jitteriness associated with stimulants

Within 48–72 hours, patients with more significant NAD+ depletion — those with post-COVID fatigue, chronic Lyme disease sequelae, or established mitochondrial dysfunction — often report their most pronounced improvements:

• Exercise tolerance increases and post-exertional malaise reduces
• Cognitive stamina improves (sustained focus without afternoon crash)
• Inflammatory joint aching may temporarily worsen before improving — a mild detoxification-like response occasionally seen in patients with significant inflammatory burden

What should prompt you to seek evaluation: True adverse reactions to NAD IV are rare but include sustained chest pain that does not resolve with rate reduction, palpitations with an irregular rhythm, or signs of anaphylaxis. These are grounds for immediate cessation and clinical assessment. In our series of several hundred infusions, we have not observed anaphylaxis with NAD+ alone, though a prior allergy to B-vitamin preparations warrants a conservative test dose and extended observation.

Dosing Protocols: How Many Sessions Do You Need?

This is not one-size-fits-all. Our practice uses three broad frameworks:

Loading protocol (acute support): 3–10 sessions over 10–21 days, doses from 500–1,000 mg per session. Reserved for severe fatigue, post-viral syndromes, and substance withdrawal support.

Performance and longevity protocol: 3–4 sessions over 2–3 weeks, doses from 250–500 mg. Designed for biologically healthy individuals seeking optimisation and anti-ageing benefit.

Maintenance protocol: Monthly or quarterly single infusions of 250–500 mg. Used to sustain elevated NAD+ alongside oral NMN or NR supplementation between sessions.

In all protocols, I pair IV NAD+ with an oral precursor regimen to maintain the gains between infusions. The IV loading effectively replenishes the pool; oral supplementation prevents the inevitable age-associated decline from consuming that reserve between visits.

Common Patient Questions

“Should I feel it working during the infusion?” Not necessarily. The therapeutic effect is largely downstream — it reflects shifts in mitochondrial function and gene expression that take hours to manifest. The infusion itself is not where the benefit happens; it is where the substrate is delivered.

“Can I combine NAD IV with other infusions?” Yes, and we routinely do. A glutathione push at the end of the session supports the antioxidant recycling that NAD+ enables. Vitamin C, phosphatidylcholine, and methylcobalamin can be co-administered in separate lines or sequentially, depending on clinical goals. The combination with high-dose vitamin C is particularly well-supported for post-viral fatigue.

“Is there a risk of tolerance — needing more over time?” The available evidence does not support a tolerance phenomenon comparable to pharmaceutical tolerance. The mechanism is substrate replenishment, not receptor modulation. Frequent high-dose infusions without oral bridging may not be the most cost-efficient approach, but they do not appear to blunt the response.

“How is this different from an NMN supplement?” The IV route delivers NAD+ precursors directly to the circulation, bypassing intestinal absorption limitations. A 500 mg IV infusion raises blood NAD+ substantially higher — and more reliably — than even the highest practical oral dose. For patients with compromised gut absorption, which is common in chronic illness, IV delivery is not just more effective; it may be the only route that achieves meaningful tissue-level NAD+ replenishment.

Related Articles

• NAD IV Therapy: Clinical Guide and Evidence Review
• NAD IV Side Effects: What’s Expected vs. What’s Concerning
• NAD vs NMN vs NR: Which Supplement Strategy Works Best?
• Post-COVID Brain Fog: Mechanisms and Treatment
• Mitochondrial Dysfunction: How It Drives Chronic Disease

References

1. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529–547. PMID: 29514063
2. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. PMID: 29599478
3. Brakedal B, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metabolism. 2022;34(3):396–407. PMID: 35235774
4. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside — the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616. PMID: 32485014
5. Radenkovic D, Verdin E. Clinical evidence for targeting NAD therapeutically. Pharmaceuticals. 2020;13(9):247. PMID: 32937830
6. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment. Biomolecules. 2020;10(5):687. PMID: 32349344
7. Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795–806. PMID: 28068222